Back to search results

Understanding Methamphetamine Isomers

This study aims to understand how your body processes different forms of methamphetamine (meth) and their effects. Methamphetamine comes in two mirror-image chemical structures: S-(+)-methamphetamine, a strong stimulant used in some medications, and R-(-)-methamphetamine, which is found in nasal decongestants. Researchers will give participants S-(+)-methamphetamine, R-(-)-methamphetamine, or a mixture of both. They will measure how much of each form is in your blood over time to understand how your body handles them. You may be able to join if you are between 21 and 64 years old, in good mental and physical health, and can speak English. The study is currently unclear on its recruitment status and plans to enroll 17 healthy participants.

Study design
This is a double-blind crossover study, meaning neither you nor the researchers will know which form of methamphetamine you receive at each visit. It will involve 17 healthy volunteers.
What's involved
You will attend three study visits, at least 7 days apart, where you will receive an intravenous (IV) dose of methamphetamine. Blood, oral fluid, and urine samples will be collected during each visit, and you will be on study for up to 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Blood samples will be collected for up to 48 hours after each dose to measure drug levels.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06746831

Methamphetamine Isomer Pharmacology in Humans

Not Yet Recruiting
PHASE1Ages 21–64InterventionalTreatment
University of Wisconsin, Madison
~17 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:S-(+)-methamphetamineR-(-)-methamphetamine1:1 racemic mixture of two isomers

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Peak concentration (Cmax)
Measured over pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
+1 more outcome measured

Conditions

Methamphetamine

Explore related trials

Healthy Volunteers

NCT06746831

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Wisconsin

    Madison, Wisconsinno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Heather K Barkholtz, PhD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison
  • David Leinweber, MD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

Heather Barkholtz, PhD
[email protected]
608-890-1967
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Good mental health as determined by self-reported responses to the Psychopathology Screener
Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener
English-speaking (able to provide consent and complete questionnaires)
Written Informed Consent

Exclusion

Any serious prior adverse response to sympathomimetic agents or amphetamine analogs
History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener
Pregnancy or lactation (pregnancy test, if needed)
Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives)
Dependent on prohibited concomitant therapy that cannot be withheld for 48 hours prior to and during study visits.

What this trial measures

  • Peak concentration (Cmax)pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours

    The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study.

  • Area under the concentration versus time curve (AUC)pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours

    The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study.